Effectiveness and safety of niraparib as neoadjuvant therapy in advanced ovarian cancer with homologous recombination deficiency: NANT study protocol for a prospective, multicenter, exploratory, phase 2, single-arm study
第一作者单位:[1]Huazhong Univ Sci & Technol,Tongji Hosp,Wuhan,Peoples R China
推荐引用方式(GB/T 7714):
Yu Yang,Zhang Wei,Liu Ronghua,et al.Effectiveness and safety of niraparib as neoadjuvant therapy in advanced ovarian cancer with homologous recombination deficiency: NANT study protocol for a prospective, multicenter, exploratory, phase 2, single-arm study[J].GYNECOLOGIC ONCOLOGY.2022,166:S28-S29.
APA:
Yu, Yang,Zhang, Wei,Liu, Ronghua,Shan, Wanying,Li, Huayi...&Gao, Qinglei.(2022).Effectiveness and safety of niraparib as neoadjuvant therapy in advanced ovarian cancer with homologous recombination deficiency: NANT study protocol for a prospective, multicenter, exploratory, phase 2, single-arm study.GYNECOLOGIC ONCOLOGY,166,
MLA:
Yu, Yang,et al."Effectiveness and safety of niraparib as neoadjuvant therapy in advanced ovarian cancer with homologous recombination deficiency: NANT study protocol for a prospective, multicenter, exploratory, phase 2, single-arm study".GYNECOLOGIC ONCOLOGY 166.(2022):S28-S29